Loading clinical trials...

Flortaucipir PET Imaging in Subjects With FTD | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Flortaucipir PET Imaging in Subjects With FTD

18F-AV-1451 PET Imaging in Subjects With Frontotemporal Dementia

NCT03040713•Avid Radiopharmaceuticals

Summary

This study is designed to assess the usefulness of flortaucipir in Positron Emission Tomography (PET) imaging for subjects diagnosed with Frontotemporal Dementia (FTD).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects diagnosed by a dementia specialist with symptomatic clinical syndromes with expected Frontotemporal Dementia (FTD) pathology will be enrolled. Clinical syndromes associated with FTD pathology include: behavioral-variant FTD, FTD with motor-neuron disease, non-fluent/agrammatic and semantic variants of primary progressive aphasia, progressive supranuclear palsy syndrome and corticobasal syndrome.
•Have provided informed consent or have a legally authorized (LAR) provide consent for study procedures
•Have had volumetric brain MRI obtained in site's companion protocol within one year of enrollment
•Can tolerate PET scan procedures

Exclusion Criteria

•Have clinically significant cardiac, hepatic, renal, pulmonary, metabolic, or endocrine disturbances that pose potential safety risk
•Have history of risk factors for Torsades de Pointes (TdP) or taking medication known to cause QT prolongation
•Have history of drug or alcohol dependence within the last year
•Are females of childbearing potential who are not surgically sterile, not refraining from sexual activity, or not using reliable contraception
•Have history of relevant severe drug allergy or hypersensitivity
•Have received an investigational medication under FDA IND protocol within 30 days of planned imaging session
•Have received a radiopharmaceutical for imaging/therapy within 24 hours of imaging session
•Possess PET scan evidence of amyloid deposition
•Determined by the investigator to be unsuitable for this type of study

Locations (3)

Movement Disorder Center, UCSD

La Jolla, California, United States

Memory and Aging Center, UCSF

San Francisco, California, United States

UT Southwestern Medical Center

Dallas, Texas, United States

Key Dates

Start Date

April 11, 2017

Primary Completion Date

October 24, 2018

Completion Date

October 24, 2018

Last Updated

September 25, 2020

Enrollment

ACTUAL participants

Conditions

Frontotemporal Dementia

Interventions

Flortaucipir F18

DRUG

Brain PET scan

PROCEDURE

Clinical Procedures to Support Research in ALS

NCT03489278

Amyotrophic Lateral SclerosisALS-Frontotemporal Dementia+2 more

View study

RECRUITINGNA

Molecular Neuroimaging of Neuroinflammation in Neurodegenerative Dementias

NCT02945774

Frontotemporal Dementia

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 25, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Flortaucipir PET Imaging in Subjects With FTD

Inclusion Criteria

Exclusion Criteria

Clinical Procedures to Support Research in ALS

Molecular Neuroimaging of Neuroinflammation in Neurodegenerative Dementias

Proteinopathies Expression in Skin of Neurodegenerative Disorders

Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder

Predict to Prevent PGRN Disease

Group-Based Telehealth Music Therapy Intervention for Patients With Dementia: A Pilot Study